(VIANEWS) – BanColombia S.A. (CIB), First Busey Corporation (BUSE), BioMarin Pharmaceutical (BMRN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. BanColombia S.A. (CIB)
31.7% sales growth and 15.74% return on equity
Bancolombia S. A. provides various banking products and services to individual and corporate customers in Colombia, Panama, Puerto Rico, El Salvador, Costa Rica, and Guatemala. The company operates through nine segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking, and All Other. It offers checking and savings accounts, fixed term deposits, and investment products; trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal and vehicle loans, payroll loans, and overdrafts; financial support to real estate developers and mortgages for individuals and companies; and financial and operating leasing services. The company also provides hedging instruments, including futures, forwards, options, and swaps; and brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign currencies, fixed income securities, mutual funds, and structured products. In addition, it offers cash management services; foreign currency transaction services; life, auto, commercial, and homeowner's insurance products; and online and computer banking services. Further, the company provides investment banking services comprising project and acquisition finance, debt and equity capital markets, principal investments, M&A, restructurings, and structured financing; money market accounts, mutual and pension funds, private equity funds, payment trust, custody, and corporate trust; and digital banking platform, transportation, securities brokerage, maintenance and remodeling, advertising and marketing, and outsourcing services, as well as credit cards. As of December 31, 2020, it operated 1,057 branches; 18,631 banking correspondents; 535 PAMs; 215 kiosks in El Salvador and 137 in Colombia; and 6,124 automatic teller machines. Bancolombia S.A. was incorporated in 1945 and is headquartered in MedellÃn, Colombia.
Earnings Per Share
As for profitability, BanColombia S.A. has a trailing twelve months EPS of $6.27.
PE Ratio
BanColombia S.A. has a trailing twelve months price to earnings ratio of 5.25. Meaning, the purchaser of the share is investing $5.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.74%.
Sales Growth
BanColombia S.A.’s sales growth is 39% for the ongoing quarter and 31.7% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 5.9% and a negative 11.5%, respectively.
Moving Average
BanColombia S.A.’s value is below its 50-day moving average of $33.03 and above its 200-day moving average of $32.40.
Yearly Top and Bottom Value
BanColombia S.A.’s stock is valued at $32.90 at 20:22 EST, way under its 52-week high of $37.85 and way higher than its 52-week low of $24.15.
2. First Busey Corporation (BUSE)
29.2% sales growth and 8.68% return on equity
First Busey Corporation operates as the bank holding company for Busey Bank that provides retail and commercial banking products and services to individual, corporate, institutional, and governmental customers in the United States. The company operates through three segments: Banking, FirsTech, and Wealth Management. It offers banking services to individual and corporate customers. The company also provides asset management, investment, brokerage, fiduciary, philanthropic advisory, tax preparation, and farm management services. Further, it offers payment technology solutions through its payment platform, such as walk-in payment processing for customers at retail pay agents; online bill payment solutions; customer service payments accepted over the telephone; mobile bill pay; direct debit services; electronic concentration of payments delivered to automated clearing house network; money management and credit card networks; and lockbox remittance processing to make payments by mail, as well as provides tools related to billing, reconciliation, bill reminders, and treasury services. The company has 46 banking centers in Illinois; 8 in Missouri; 3 in southwest Florida; and 1 in Indianapolis, Indiana. First Busey Corporation was founded in 1868 and is headquartered in Champaign, Illinois.
Earnings Per Share
As for profitability, First Busey Corporation has a trailing twelve months EPS of $1.94.
PE Ratio
First Busey Corporation has a trailing twelve months price to earnings ratio of 12.68. Meaning, the purchaser of the share is investing $12.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.68%.
3. BioMarin Pharmaceutical (BMRN)
14.1% sales growth and 5.1% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $1.32.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 67.15. Meaning, the purchaser of the share is investing $67.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.1%.
Sales Growth
BioMarin Pharmaceutical’s sales growth is 15.6% for the current quarter and 14.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.6%, now sitting on 2.59B for the twelve trailing months.
4. Addus HomeCare Corporation (ADUS)
9.1% sales growth and 8.68% return on equity
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.
Earnings Per Share
As for profitability, Addus HomeCare Corporation has a trailing twelve months EPS of $4.2.
PE Ratio
Addus HomeCare Corporation has a trailing twelve months price to earnings ratio of 29.67. Meaning, the purchaser of the share is investing $29.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.68%.
Moving Average
Addus HomeCare Corporation’s value is higher than its 50-day moving average of $118.91 and way higher than its 200-day moving average of $100.52.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 11.3% and 3%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.4%, now sitting on 1.11B for the twelve trailing months.
5. Progyny (PGNY)
8.9% sales growth and 13.56% return on equity
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Progyny has a trailing twelve months EPS of $0.63.
PE Ratio
Progyny has a trailing twelve months price to earnings ratio of 34.24. Meaning, the purchaser of the share is investing $34.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.56%.
6. CBIZ (CBZ)
7.7% sales growth and 14.11% return on equity
CBIZ, Inc. provides financial, insurance, and advisory services in the United States and Canada. The company operates through three segments: Financial Services, Benefits and Insurance Services, and National Practices. The Financial Services segment offers accounting and tax, government healthcare consulting, financial advisory, valuation, and risk and advisory services. The Benefits and Insurance Services provides group health benefits consulting, payroll, property and casualty, and retirement plan services. The National Practices segment offers managed networking and hardware, and health care consulting services. It primarily serves small and medium-sized businesses, as well as individuals, governmental entities, and not-for-profit enterprises. The company was founded in 1987 and is headquartered in Cleveland, Ohio.
Earnings Per Share
As for profitability, CBIZ has a trailing twelve months EPS of $2.33.
PE Ratio
CBIZ has a trailing twelve months price to earnings ratio of 30.91. Meaning, the purchaser of the share is investing $30.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.11%.
Yearly Top and Bottom Value
CBIZ’s stock is valued at $72.02 at 20:22 EST, way under its 52-week high of $86.36 and way higher than its 52-week low of $49.15.
Sales Growth
CBIZ’s sales growth is 7.2% for the present quarter and 7.7% for the next.
